Pfizer's Sutent Expanded Indication: 'Hope' Or 'False Hope'?

US FDA Oncologic Drugs Advisory Committee casts tie vote on proposed expansion of Sutent's renal cell carcinoma indication, mirroring debate FDA having internally.

FDA Advisory Committee Feature image
Oncologic Drugs Advisory Committee votes 6-6 on whether the risk-benefit profile for Sutent's indication expansion is acceptable.

The US FDA's Oncologic Drugs Advisory Committee, just like the agency itself, struggled to determine whether Pfizer Inc.'s Sutent (sunitinib) provides clinical benefit as an adjuvant treatment of renal cell carcinoma, offering no definitive recommendation.

The committee tied with a 6-6 vote Sept. 19 on whether the risk-benefit profile was acceptable as adjuvant treatment in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA Performance Tracker

More from Regulatory Trackers